Top Medical News
2 days ago
The efficacy and compliance related to percutaneous tibial nerve stimulation (PTNS) are both favourable in traditionally underserved patients treated for overactive bladder at a large urban safety net hospital, reports a study.
Stephen Padilla, 4 days ago
Adherence to a low-fat diet is associated with lower serum testosterone levels among men even when controlling for comorbidities, age, body mass index (BMI) and activity levels, according to a US study.
12 Jan 2020
Whole-pelvis radiotherapy (WPRT) improves biochemical recurrence-free survival (bRFS), but not distant metastasis-free survival (DMFS) and prostate cancer-specific survival (PCSS), in patients with Gleason grade group 5 prostate cancer (PCa) treated with either external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT), a recent study has found.
12 Jan 2020
Mirabegron may be used to effectively treat overactive bladder (OAB) syndrome without presenting new and pressing safety concerns, a recent study has found.
Audrey Abella, 10 Jan 2020
The addition of the oral phosphodiesterase-5 (PDE-5) inhibitor pentoxifylline to sildenafil failed to show benefit in men with erectile dysfunction (ED) with suboptimal response to sildenafil, a Singapore study shows.
07 Jan 2020
Point-of-care ultrasound (POCUS) in emergency settings accurately detects testicular torsion in children, a recent study has found.
07 Jan 2020
Men who are prescribed opioids for minor urologic surgeries are more likely to develop persistent long-term opioid use, a recent study has found.
Special Reports
26 Nov 2019
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
15 Mar 2019
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Conference Reports
Pank Jit Sin, 03 Sep 2019

Immunotherapy, in the setting of advanced prostate cancer (PCa), may alter the lethal condition of advanced PCa into a chronic disease with significantly longer overall survival (OS), says an expert. 
Jackey Suen, 06 Mar 2019

The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.

Dr. Joseph Delano Fule Robles, 04 Mar 2019

Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.

Dr. Joseph Delano Fule Robles, 22 Feb 2019

Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.

Jackey Suen, 30 Jan 2019

Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.

Audrey Abella, 11 May 2018
Nanotechnology structured water was similarly effective as tadalafil in improving erectile function, suggesting that it could be a potential treatment option for erectile dysfunction (ED), according to a study presented at EAU held in Copenhagen, Denmark.
Audrey Abella, 30 Apr 2018
The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.